Get the Stockscreener App
5.36
3.68%
0.19
After Hours:
5.10
-0.26
-4.85%
Zura Bio Ltd stock is traded at $5.36, with a volume of 925.99K.
It is up +3.68% in the last 24 hours and up +57.65% over the past month.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
See More
Previous Close:
$5.17
Open:
$5.13
24h Volume:
925.99K
Relative Volume:
0.94
Market Cap:
$508.56M
Revenue:
-
Net Income/Loss:
$-75.43M
P/E Ratio:
-4.3931
EPS:
-1.2201
Net Cash Flow:
$-72.75M
1W Performance:
-4.80%
1M Performance:
+57.65%
6M Performance:
+10.97%
1Y Performance:
+374.34%
1-Day Range:
$5.03
$5.43
1-Week Range:
$4.94
$6.01
52-Week Range:
$1.08
$7.44
Zura Bio Ltd Stock (ZURA) Company Profile
Name
Zura Bio Ltd
Sector
Industry
Phone
858-247-0520
Address
4225 EXECUTIVE SQUARE, LA JOLLA
Compare ZURA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZURA
Zura Bio Ltd
|
5.36 | 559.80M | 0 | -75.43M | -72.75M | -1.2201 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Initiated | Wedbush | Outperform |
| Nov-04-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| May-03-24 | Initiated | Piper Sandler | Overweight |
| Oct-10-23 | Initiated | Ladenburg Thalmann | Buy |
| Aug-25-23 | Initiated | Oppenheimer | Outperform |
| Jun-22-23 | Initiated | Guggenheim | Buy |
| Jun-14-23 | Initiated | Chardan Capital Markets | Buy |
| May-24-23 | Initiated | Raymond James | Strong Buy |
View All
Zura Bio Ltd Stock (ZURA) Latest News
Zura Bio’s Tibulizumab: First Dual BAFF & IL-17 Bispecific Antibody for Complex Autoimmune Diseases, Advancing in Phase 2 Trials – Minichart - Minichart
Zura Bio updates corporate presentation; tibulizumab Phase 2 toplines, $225.6M cash (Mar 31, 2026) - TradingView
Zura Bio (NASDAQ: ZURA) furnishes updated corporate presentation for investors - Stock Titan
We're Hopeful That Zura Bio (NASDAQ:ZURA) Will Use Its Cash Wisely - simplywall.st
Zura Bio completes enrollment in tibulizumab trials By Investing.com - Investing.com South Africa
ZURA Financial Update: Cash Position and Operational Outlook - GuruFocus
Zura Bio completes Phase 2 trial enrollment for tibulizumab in hidradenitis suppurativa - Traders Union
Zura Bio clears enrollment targets in two Phase 2 studies, adds a third - Stock Titan
Zura Bio Ltd (ZURA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Zura Bio (ZURA) VP details share, RSU and option holdings - Stock Titan
Zura Bio | 4: Statement of changes in beneficial ownership of securities-Director Jarrett Jennifer - Moomoo
Zura Bio (NASDAQ: ZURA) director receives grant of 51,000 share options - Stock Titan
Zura Bio (ZURA) director awarded 51,000 share options at $3.62 - Stock Titan
Zura Bio (ZURA) director receives grant of 51,000 stock options - Stock Titan
Zura Bio (ZURA) director Amit Munshi granted 51,000 share options at $3.62 - Stock Titan
Zura Bio (ZURA) director Daniel Becker receives 51,000 share options at $3.62 - Stock Titan
Director at Zura Bio (NASDAQ: ZURA) granted 51,000 stock options - Stock Titan
Zura Bio (ZURA) director receives 51,000 share options at $3.62 strike price - Stock Titan
Zura Bio | 4: Statement of changes in beneficial ownership of securities-Director Munshi Amit - Moomoo
Zura Bio StockSaturday look at the business model and pipeline - AD HOC NEWS
Zura Bio (NASDAQ: ZURA) investors approve board slate, auditor and 2023 equity plan changes - Stock Titan
Zura Bio Ltd (ZURA) Institutional Confidence - TradingKey
Zura Bio Ltd (ZURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Zura Bio Ltd (ZURA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Zura Bio Ltd (ZURA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Zura Bio Ltd (ZURA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Zura Bio Ltd (ZURA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Zura Bio Ltd (ZURA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Zura Bio Ltd (ZURA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Zura Bio Ltd stock (KYG989201089): Pipeline update and capital raise reshape the story - AD HOC NEWS
Here's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Situation - Yahoo Finance
ZURAZura Bio Ltd Stock Price and Quote - Finviz
Zura Bio (NASDAQ: ZURA) discloses resignation of director Someit Sidhu - Stock Titan
Zura Bio Ltd stock (KYG989201089): pipeline update keeps autoimmune story in focus - AD HOC NEWS
Venrock entities report 9.99% ownership in ZURA (ZURA) - Stock Titan
Great Point Partners, Dr. Jay & Nordahl report 4.44% in ZURA (ZURA) - Stock Titan
Zura Bio reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Zura Bio stock (KYG989201089): Appoints Muzammil Mustufa as Chief Business Officer - AD HOC NEWS
Zura Bio's new CBO gets options on 600,000 shares at $4.80 - Stock Titan
Zura Bio appoints Muzammil Mustufa as chief business officer By Investing.com - Investing.com Canada
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer - ChartMill
TradingKey - TradingKey
Suvretta/Averill disclose large ZURA stakes (NASDAQ: ZURA) in 13G/A filing - Stock Titan
Jessica Chen - White & Case LLP
Zura Bio Limited (NASDAQ:ZURA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Insider Purchases Worth US$12.5m See Losses As Zura Bio Market Value Drops To US$464m - simplywall.st
Zura Bio Ltd 1Q 2026: Net income $(24.2M), EPS $(0.22) — 10-Q Summary - TradingView
Zura Bio (Nasdaq: ZURA) widens Q1 loss, boosts cash to $225.6M - Stock Titan
Zura Bio (NASDAQ: ZURA) boosts cash with $134.6M raise as R&D loss deepens - Stock Titan
Zura Bio Limited Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates - ChartMill
Zura Bio Ltd Stock (ZURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):